The ED50 of intrathecal injection of ropivacaine during cervical cerclage

Comparison of the ED50 of intrathecal hyperbaric ropivacaine co-administered with or without intrathecal dexmedetomidine for cervical cerclage: a prospective, double-blinded, randomized dose-response trial using up-down sequential allocation method

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050820

Enrollment

Unknown

Registered

2021-09-04

Start date

2021-09-15

Completion date

Unknown

Last updated

2022-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical insufficiency

Interventions

Ropivacaine group:Ropivacaine

Ropivacaine and dexmedetomidine group:Ropivacaine and dexmedetomidine

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women who intend to have a selective cervical cerclage procedure performed before or during pregnancy (from 1st week to 26th week).

Exclusion criteria

Exclusion criteria: Being afflicted with neurological diseases or suffering from back pain.

Design outcomes

Primary

Measure	Time frame
Anesthetic effect;	—

Secondary

Measure	Time frame
Visual analogue pain score;Modified bromage score;Hypotension;	—

Countries

China

Contacts

Public ContactZhou Min

Fujian Provincial Maternity and Children's Hospital

zm405@163.com+86 13850101696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026